Affecting nine percent of the adult population, diabetes is one of the major causes of disability and death worldwide. It also brings a huge and growing economic burden: in the US alone, health care costs for people diagnosed with diabetes account for more than 200 percent of the costs for others.
Today life sciences companies are continuing their search for new treatments, preventions and cures. The growing incidence and diagnosis of type II diabetes brings additional requirements for testing drugs and devices designed to control cardiac, renal and other conditions that commonly arise in the diabetic population. At the same time, the environment of medical research is becoming increasingly complex, regulation-driven and reimbursement-sensitive, adding time and complexity to the development of new treatments.